– FRANCE, Nîmes – Advicenne (EPA: ADVIC), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for orphan renal and neurological diseases, today announced that Dr Luc-André Granier has left his role as CEO of the Company and that the Board of Directors has elected Dr André Ulmann, current Board Observer of the company, as Interim CEO of Advicenne, effective immediately.
“I welcome André Ulmann whose experience and medical development skills will be instrumental to the further growth and success of Advicenne.” said David Horn Solomon, Chairman.
The search for a permanent CEO is ongoing.
“On behalf of our Board of Directors, I would like to thank Luc-André Granier for his valuable involvement and contributions as CEO. As one of the founders and CEO of the company, he has contributed significantly to building and advancing Advicenne and has positioned the company for success.”
About Dr. André Ulmann
Dr. André Ulmann has over thirty years’ experience as a Pharmaceutical Industry executive in various positions. André joined Roussel Uclaf (later Sanofi Aventis) where he led R&D in endocrinology and neurology. In 1996, he created and led HRA Pharma for more than 20 years, a company specialized in women’s health and rare diseases and oncology. He grew the company from inception to more than €100m sales in 2017. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill”. Norlevo is now available in more than fifty countries and HRA Pharma is considered a pioneer in emergency contraception. The company was acquired in 2016 in a major Private Equity transaction. Andre also serves on Asarina (STO: ASAP) and has served on Advicenne board since 2008. In 2018, André was the recipient of the First John Baxter award for Entrepreneurship given by the American Endocrine Society.
André Ulmann said “As a long-standing scientific, corporate and financial supporter of Advicenne, I am honored and excited to be able to bring the company through its next decisive milestones over 2020 in close cooperation with Chairman David Horn Solomon and Advicenne’s board. ADV7103 is close to European approval and is a potential breakthrough product that fulfills great unmet medical needs in dRTA and cystinuria, two orphan indications currently not well served. I look forward to contributing advances toward the commercialization of our first product.”
Dr. Ulmann is a Doctor of Medicine and Doctor of Science from the University of Paris and began his career practicing Nephrology at Hôpital Necker (Paris, France), where he was responsible for the care of cystinuria patients.
Advicenne (Euronext ADVIC) is a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare kidney disease.
In 2017, ADV7103 was granted orphan drug designation by the European Commission in the treatment of distal renal tubular acidosis (dRTA), a serious condition that occurs when the kidneys are unable to effectively remove the buildup of circulating acids in the blood, resulting in a metabolic imbalance.
ADV7103 is currently in Phase III clinical trials for dRTA in the United States and Canada. In 2019, a European marketing authorization application for the drug candidate in the treatment of dRTA was submitted for a centralized review.
At Advicenne, we are committed to innovating in the areas of formulation and dosage. Tasteless and easy to administer, our products are commercialized in small-size formats that offer flexible, personalized dosing – because path-breaking treatments for rare diseases should be available to patients of all ages.
Headquartered in Nîmes, France, Advicenne has been listed on the Euronext Paris stock exchange since 2017 and was cross-listed on the Euronext Brussels stock exchange in 2019.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.